BRIEF-Astrazeneca Says Tremelimumab Accepted Under Priority Review In U.S.

Reuters | Updated: 25-04-2022 12:17 IST | Created: 25-04-2022 12:15 IST
BRIEF-Astrazeneca Says Tremelimumab Accepted Under Priority Review In U.S.
Representative Image Image Credit: Twitter (@AstraZeneca)

AstraZeneca PLC:

* ASTRAZENECA PLC - TREMELIMUMAB US PRIORITY REVIEW FOR IMFINZI COMBO

* ASTRAZENECA - TREMELIMUMAB ACCEPTED UNDER PRIORITY REVIEW IN US FOR PATIENTS WITH UNRESECTABLE LIVER CANCER IN COMBINATION WITH IMFINZI Source text for Eikon: Further company coverage:

TRENDING

1
Johor Elections: A Test of Unity for Anwar Ibrahim's Coalition

Johor Elections: A Test of Unity for Anwar Ibrahim's Coalition

Global
2
Apple Sues OpenAI: The Battle for AI Hardware Heats Up

Apple Sues OpenAI: The Battle for AI Hardware Heats Up

Global
3
Trump's Controversial Ousting at the Federal Election Agency

Trump's Controversial Ousting at the Federal Election Agency

Global
4
Controversy Over Trump Administration's Shake-Up of Election Agency

Controversy Over Trump Administration's Shake-Up of Election Agency

Global

PERSPECTIVES AND INSIGHTS

The Next Global Health Crisis Is Already Here and It Is Drug-Resistant

AI in African Higher Education: Innovation’s Promise, Inequality’s Warning

Urban-Rural Coordination Is Becoming the New Test of Sustainable Development

South Africa’s Poor Are Banked, But Still Financially Excluded

DevShots

Latest News

Connect us on

LinkedIn Quora Youtube RSS
Give Feedback

Use this form for editorial or site feedback. We usually reply within 2 to 3 working days.

By submitting, you agree that we may use your email address to respond.

Subscribe to our Newsletter  

STANDARDS & POLICIES

EDITIONS

OTHER LINKS

CONNECT

Devdiscourse
Disclaimer | Terms of use | Privacy Policy

© Copyright 2026